Sosei Heptares' Partner, Pfizer, Progresses Its GLP-1
PF-06954522 was introduced into Pfizer’s Internal Medicine focused clinical pipeline as part of its Q3 2023 results presentation Tokyo, Japan and...
Source: globenewswire.com
📰 Sosei Group News
Page 2 - Sosei Group News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Sosei Group. Real-time updates on events, politics, business and more.
Daridorexant for Insomnia Nears Approval in Japan
A new drug application has been submitted in Japan for the approval of daridorexant, a dual orexin receptor antagonist for insomnia.
Sosei Heptares Makoto Uchiyama Nihon University Mochida Pharmaceutical Co Ltd Idorsia Pharmaceuticals Ltd Idorsia Pharmaceuticals Japan Ltd
Source: sleepreviewmag.com
Idorsia Shares Fall on Funding Needs
By Helena Smolak Idorsia shares fell after the company said it continues to look for funding, given that a recent sale of assets to Sosei Group and cost...
Helena Smolak Andrec Muller Sosei Group Chief Financial Officer Andre Article Normal Biotechnology Services
Source: marketwatch.com
4565 Stock Price | Sosei Group Corp. Stock Quote (Japan: Tokyo)
4565 | Complete Sosei Group Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Shinichi Tamura Sosei Group Corp Sosei Group Stabilised Receptor Takaya Nakamura 565 Analyst Estimates
Source: marketwatch.com
Sosei Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic Development
Nomination of novel drug target based on insights generated through application of Verily’s Immune Profiler platform and Sosei Heptares’ GPCR-focused structure-based drug design expertise ...
Source: marketscreener.com
biocon: Biocon appoints Peter Bains as group CEO - The Economic Times
He has over 30 years of global experience in strategic and operational leadership, including at board, CEO and senior corporate levels. He served as CEO and on the Board of Syngene International Ltd, a subsidiary of the company, for almost 6 years from 2010, and led the company to its successful public listing in 2015, Biocon said.
United Kingdom Peter Bains Healthcare Management Analytics Programme Board Of Biocon Ltd Biocon Group Board Of Syngene International Ltd
Source: indiatimes.com
Biocon ropes in Peter Bains as group CEO
Biocon appoints Peter Bains as group CEO, effective immediately. Bains has over 30 years of global experience in leadership roles.
Source: livemint.com
Sosei Heptares' partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults -Today at 07:01 pm
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric...
Source: marketscreener.com
Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732
HTL0039732 is a novel EP4 antagonist designed by Sosei Heptares with potential to treat a wide range of cancers in combination with other immunotherapies Tokyo, Japan, London and Cambridge, UK, 10 August 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world-leader in GPCR-focused structure-based drug design (SBDD) and development, and Cancer Research UK, the world’s largest independent funder of cancer research, today announce that the first patient has...
Source: yahoo.com
Sosei Heptares Operational Highlights and Consolidated
Tokyo, Japan and Cambridge, UK, 4 August 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports...
Source: globenewswire.com